PCSK9 and myocardial infarction: The EPIC STEMI (effects of routine early treatment with PCSK9 inhibitors inpatients undergoing primary percutaneous coronary intervention for ST-segmentelevation myocardial infarction) trial [69] is an investigator-initiatedrandomized, double-blind, placebo-controlled clinical study assessing the impactof alirocumab on lowering lipid levels in ACS ST- elevation MI (STEMI) patientsundergoing PCI.